Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

  1. Bahlis, N.J.
  2. Dimopoulos, M.A.
  3. White, D.J.
  4. Benboubker, L.
  5. Cook, G.
  6. Leiba, M.
  7. Ho, P.J.
  8. Kim, K.
  9. Takezako, N.
  10. Moreau, P.
  11. Kaufman, J.L.
  12. Krevvata, M.
  13. Chiu, C.
  14. Qin, X.
  15. Okonkwo, L.
  16. Trivedi, S.
  17. Ukropec, J.
  18. Qi, M.
  19. San-Miguel, J.
Journal:
Leukemia

ISSN: 1476-5551 0887-6924

Year of publication: 2020

Volume: 34

Issue: 7

Pages: 1875-1884

Type: Article

DOI: 10.1038/S41375-020-0711-6 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals